MedPath

Atovaquone

These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION. ATOVAQUONE oral suspensionInitial U.S. Approval: 1992

Approved
Approval ID

c61aa490-5b55-4ba9-b107-bb37f1fa352b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 24, 2023

Manufacturers
FDA

VistaPharm, LLC

DUNS: 116743084

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Atovaquone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code66689-062
Application NumberANDA202960
Product Classification
M
Marketing Category
C73584
G
Generic Name
Atovaquone
Product Specifications
Route of AdministrationORAL
Effective DateFebruary 24, 2023
FDA Product Classification

INGREDIENTS (9)

ATOVAQUONEActive
Quantity: 750 mg in 5 mL
Code: Y883P1Z2LT
Classification: ACTIB
BENZYL ALCOHOLInactive
Code: LKG8494WBH
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SACCHARIN SODIUMInactive
Code: SB8ZUX40TY
Classification: IACT
POLOXAMER 188Inactive
Code: LQA7B6G8JG
Classification: IACT
XANTHAN GUMInactive
Code: TTV12P4NEE
Classification: IACT
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
TRIACETINInactive
Code: XHX3C3X673
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Atovaquone - FDA Drug Approval Details